BMC Pulmonary Medicine最新文献

{"title":"Cough duration, energy and sound frequency in COVID-19 patients: the spectral analysis results.","authors":"Andrey V Budnevsky, Djuro Kosanovic, Evgeniy S Ovsyannikov, Oleg N Choporov, Alexander V Pertsev, Sofia N Feigelman, Tatiana A Chernik, Alexey V Maksimov, Galina G Prozorova, Svetlana A Kozhevnikova, Roman E Tokmachev, Anastasiya V Belyakova, Valeria R Drobysheva, Sergey N Avdeev","doi":"10.1186/s12890-025-03846-z","DOIUrl":"10.1186/s12890-025-03846-z","url":null,"abstract":"<p><strong>Background: </strong>Cough is one of the most common clinical manifestations of COVID-19. Objective of our study was to perform analysis of cough duration, energy and sound frequency in COVID-19 patients, compared to induced cough in controls and the cough in asthma and chronic obstructive pulmonary disease (COPD) patients.</p><p><strong>Methods: </strong>The following characteristics of cough sounds were obtained: duration, Q coefficient - low/medium-frequency energy (60-600 Hz) to high-frequency energy (600-6000 Hz) ratio, and frequency of maximum sound energy. The cough was divided into three phases and assessment of characteristics was applied to the entire coughing act and to each phase separately in controls and patients with COVID-19, asthma and COPD.</p><p><strong>Results: </strong>The cough sounds of COVID-19 patients were characterized by a shorter duration, a predominance of high-frequency energy and higher maximum frequency of the energy, compared with the induced cough of controls. However, the frequencies of the maximum sound energy of the individual cough phases did not differ significantly, as did the duration of the first phase. In addition, the significant differences were demonstrated in some time-frequency parameters of cough sounds in the patients with asthma and COPD as compared to COVID-19 patients.</p><p><strong>Conclusion: </strong>Therefore, we have shown the distinction between the cough characteristics of COVID-19 patients compared to controls and patients with asthma or COPD.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"367"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of an artificial intelligence-based lung CT airway model in the quantitative evaluation of large and small airway lesions in patients with chronic obstructive pulmonary disease.","authors":"Zheng Liu, Jing Li, Bo Li, Guozhen Yi, Shaoqian Pang, Ruinan Zhang, Peixiu Li, Zhaoping Yin, Jing Zhang, Bingxin Lv, Jingjing Yan, Jiao Ma","doi":"10.1186/s12890-025-03848-x","DOIUrl":"10.1186/s12890-025-03848-x","url":null,"abstract":"<p><strong>Background: </strong>Accurate quantification of the extent of bronchial damage across various airway levels in chronic obstructive pulmonary disease (COPD) remains a challenge. In this study, artificial intelligence (AI) was employed to develop an airway segmentation model to investigate the morphological changes of the central and peripheral airways in COPD patients and the effects of these airway changes on pulmonary function classification and acute COPD exacerbations.</p><p><strong>Methods: </strong>Clinical data from a total of 340 patients with COPD and 73 healthy volunteers were collected and compiled. An AI-driven airway segmentation model was constructed using Convolutional Neural Regressor (CNR) and Airway Transfer Network (ATN) algorithms. The efficacy of the model was evaluated through support vector machine (SVM) and random forest regression approaches.</p><p><strong>Results: </strong>The area under the receiver operating characteristic (ROC) curve (AUC) of the SVM in evaluating the COPD airway segmentation model was 0.96, with a sensitivity of 97% and a specificity of 92%, however, the AUC value of the SVM was 0.81 when it was replaced the healthy group by non-COPD outpatients. Compared with the healthy group, the grade and the total number of airway segmentation were decreased and the diameters of the right main bronchus and bilateral lobar bronchi of patients with COPD were smaller and the airway walls were thinner (all P < 0.01). However, the diameters of the subsegmental and small airway bronchi were increased, and airway walls were thickened, and the arc lengths were shorter ( all P < 0.01), especially in patients with severe COPD (all P < 0.05). Correlation and regression analysis showed that FEV1%pre was positively correlated with the diameters and airway wall thickness of the main and lobar airway, and the arc lengths of small airway bronchi (all P < 0.05). Airway wall thickness of the subsegment and small airway were found to have the greatest impact on the frequency of COPD exacerbations.</p><p><strong>Conclusion: </strong>Artificial intelligence lung CT airway segmentation model is a non-invasive quantitative tool for measuring chronic obstructive pulmonary disease. The main changes in COPD patients are that the central airway diameter becomes narrower and the thickness becomes thinner. The arc length of the peripheral airway becomes shorter, and the diameter and airway wall thickness become larger, which is more obvious in severe patients. Pulmonary function classification and small and medium airway dysfunction are also affected by the diameter, thickness and arc length of large and small airways. Small airway remodeling is more significant in acute exacerbations of COPD.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"371"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical study on the role of modified chest drainage tube in enhanced recovery after uniportal VATS radical surgery for lung cancer.","authors":"Wei Zheng, Pingli Wang, Zengzhen Cao","doi":"10.1186/s12890-025-03853-0","DOIUrl":"10.1186/s12890-025-03853-0","url":null,"abstract":"<p><strong>Objective: </strong>This study evaluates the impact of a modified chest drainage tube on postoperative recovery and its clinical application value by comparing the drainage efficacy of the modified tube with conventional chest drainage tubes after uniportal video-assisted thoracoscopic surgery (VATS) for lung cancer.</p><p><strong>Methods: </strong>A retrospective analysis of clinical data from 100 patients who underwent uniportal VATS radical surgery for lung cancer in the department of thoracic and cardiovascular surgery at our hospital between January 2023 and January 2024 was conducted. Of these, 50 patients received the modified chest drainage tube postoperatively (experimental group), while 50 patients received the conventional chest drainage tube (control group). Postoperative outcomes, including thoracic drainage volume, duration of chest tube placement, length of hospital stay, wound healing, pain levels, and tube reinsertion rates, were compared between the two groups.</p><p><strong>Results: </strong>The experimental group demonstrated significantly improved outcomes in terms of chest tube placement duration, length of hospital stay, wound healing, and pain levels compared to the control group, with statistically significant differences (P < 0.05). However, no statistically significant differences were observed between the two groups regarding postoperative thoracic drainage volume and tube reinsertion rates (P > 0.05).</p><p><strong>Conclusion: </strong>The modified chest drainage tube used after uniportal VATS radical surgery for lung cancer exhibits safety and efficacy, facilitates rapid recovery, and demonstrates potential clinical value.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"369"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317644/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amivantamab versus standard therapies among patients with advanced non-small cell lung cancer and epidermal growth factor receptor exon 20 insertion mutations after platinum-based therapy in China.","authors":"Lan Shen, Guangyuan Hu, Yan Wang, Jing Zhao, Xin Li, Jianmin Zhuo, Grace Kah Mun Low, Shun Lu","doi":"10.1186/s12890-025-03826-3","DOIUrl":"10.1186/s12890-025-03826-3","url":null,"abstract":"<p><strong>Objectives: </strong>There is limited data on the unmet needs of advanced non-small cell lung cancer (aNSCLC) patients with epidermal growth factor receptor exon 20 insertion mutations (EGFR exon20ins) in China. The single-arm CHRYSALIS study (NCT02609776) demonstrated durable responses of amivantamab monotherapy among aNSCLC patients with EGFR exon20ins after platinum-based chemotherapy. We aimed to leverage real-world data to describe the unmet needs of these patients and explore the clinical benefits of amivantamab monotherapy through indirect comparison to an external control (EC) from China.</p><p><strong>Materials and methods: </strong>Eligible patients with any systemic anti-cancer therapy (SACT) after the aNSCLC diagnosis were identified from the electronic medical records of three tertiary medical institutions. Clinical outcomes and treatment patterns were compared between patients with exon20ins and common EGFR (cEGFR) mutations. Effectiveness comparison, including real-world progression-free survival (rwPFS), real-world time to next therapy (rwTTNT) and real-world objective response rate (rwORR) was conducted between CHRYSALIS patients and the EC. Propensity score weighting was used to adjust the baseline characteristics between two cohorts. Real-world outcomes were compared between two cohorts using weighted Cox proportional hazards regression models.</p><p><strong>Results: </strong>EGFR exon20ins patients (n = 60) under SACT had significantly shorter median rwPFS (9.36 vs. 12.42 months) and rwTTNT (9.82 vs. 16.49 months) compared to cEGFR patients (n = 753). The majority of first-line treatment for exon20ins patients was platinum-based regimens (n = 52, 86.7%). Patients from CHRYSALIS and EC cohort were included in the analysis at each qualifying line of therapy (n = 114 and n = 87). Amivantamab-treated patients had significantly improved median rwPFS (6.93 vs. 5.62 months; P = 0.0133), rwTTNT (12.16 vs. 6.01 months; P = 0.0024), and significantly higher rwORR (36.8% vs. 1.0%; P < 0.0001) than EC cohort. Real-world overall survival was numerically longer in amivantamab-treated patients (23.13 vs. 11.63 months; P = 0.1911).</p><p><strong>Conclusion: </strong>Chinese patients with EGFR exon20ins under SACT had poor clinical outcomes comparing to those with common EGFR mutations in the study. The clinical benefit of amivantamab monotherapy for exon20ins patients was demonstrated through comparing to a real-world EC under standard of care. Amivantamab monotherapy may be considered as a potential effective treatment option for the Chinese patients harboring exon20ins.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"364"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12315348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic efficacy of Mycoplasma pneumoniae antibody and procalcitonin in children with Mycoplasma pneumonia.","authors":"Zhe Zhang, Boying Wu, Qijun Wang, Qiaoyi Xie","doi":"10.1186/s12890-025-03870-z","DOIUrl":"10.1186/s12890-025-03870-z","url":null,"abstract":"<p><strong>Background: </strong>The prognosis of children with Mycoplasma pneumoniae pneumonia (MPP) is significantly impacted by the possibility of a missed or delayed diagnosis during the early stages of the illness. In this study, we assessed the potential of utilizing MP antibody and procalcitonin levels as diagnostic markers in pediatric patients with MPP, and their correlation with drug-resistance gene mutations.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 80 hospitalized children with MPP confirmed by 23 S PCR and 80 healthy controls, focusing on serum MP antibody and procalcitonin (PCT) levels. The diagnostic value was assessed using receiver operating characteristic (ROC) curves. Additionally, PCR combined with TaqMan fluorescent probe technology was utilized to detect drug-resistance gene mutations in the MPP group.</p><p><strong>Results: </strong>The observation group exhibited significantly higher positive rates of MP antibody and PCT compared to the control group (28.75% vs. 8.75% and 72.50% vs. 18.75%, respectively; P < 0.05). ROC analysis revealed areas under the curve (AUCs) of 0.700 (95% CI: 0.623-0.770) and 0.779 (95% CI: 0.707-0.841) for MP antibody and PCT, respectively, with a combined diagnostic AUC of 0.869 (95% CI: 0.806-0.917) (P < 0.05). Furthermore, 22.5% of children with MPP exhibited drug-resistance gene mutations, associated with increased MP antibody and PCT levels.</p><p><strong>Conclusion: </strong>MP antibody and PCT levels are promising markers for diagnosing MPP in children, offering enhanced diagnostic value when used in combination. Furthermore, the presence of MP drug resistance gene mutations is associated with increased MP antibody and PCT levels, suggesting that these markers may have potential utility in guiding treatment strategies. Further research is needed to confirm their role in improving patient outcomes.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"370"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral and pulmonary telomere lengths in patients with non-idiopathic pulmonary fibrosis interstitial lung diseases.","authors":"Yujie Shi, Yanyan Li, Ruxuan Chen, Nan Fang, Mengqi Wang, Zhiyi Li, Qi Chen, Chi Shao, Mingbao Lin, Hui Huang","doi":"10.1186/s12890-025-03865-w","DOIUrl":"10.1186/s12890-025-03865-w","url":null,"abstract":"<p><strong>Introduction: </strong>Telomere and telomerase abnormalities play critical roles in interstitial lung diseases (ILDs). This study aimed to explore the telomere lengths (TL) in cells in the peripheral blood and bronchoalveolar lavage fluid (BALF) of healthy individuals and patient with various types of non-idiopathic pulmonary fibrosis (IPF)-ILD and to evaluate the correlation between TL and clinical indicators.</p><p><strong>Methods: </strong>We enrolled 48 patients with ILDs and 21 control individuals who presented at our hospital from September 2023 to September 2024. The relative TL of genomic deoxyribonucleic acid (DNA) in peripheral blood mononuclear cells (PBMCs) and BALF macrophages were measured using quantitative polymerase chain reaction (qPCR).</p><p><strong>Results: </strong>Patients with non-IPF-FILD had significantly shorter PBMC TL than controls (p < 0.001) and non-F-ILD patients (p < 0.001). There was a linear correlation between the TL in cells in the BALF and peripheral blood. Compared with control individuals, patients with non-F-ILD also had no significant difference in TL in cells both in the PBMC and BALF. TL was strongly associated with the presence of autoantibodies (η² = 0.275, p = 0.012) and the use of immunosuppressants (η² = 0.246, p = 0.010).</p><p><strong>Conclusions: </strong>The PBMC TL of non-IPF-FILD patients were significantly shorter than that of control and non-F-ILD patients. However, there was no significant difference in TL in cells in the BALF and peripheral blood between non-F-ILD patients and control individuals. TL were closely correlated with the presence of autoantibodies and treatment with immunosuppressants.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"368"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Krebs von den Lungen-6 as a potential biomarker for early diagnosis of silicosis: a case-control study.","authors":"Qiying Nong, Xuehua Zhu, Lin Zhong, Ying Li, Liang Yao, Zhiming Hu, Shan Wu, Ziping Zou, Cong Li, Zhifang Liu, Kengkeng Chen, Bizhu Zhang, Wei Wei, Yiru Qin, Yongshun Huang, Na Zhao, Lihua Xia","doi":"10.1186/s12890-025-03820-9","DOIUrl":"10.1186/s12890-025-03820-9","url":null,"abstract":"<p><strong>Background: </strong>Silicosis is an irreversible and progressive pulmonary fibrosis that results in prolonged inhalation of crystalline silica. Despite its significant impact, no specific blood biomarkers currently exist for the early diagnosis of this disease. This study aims to evaluate the levels of Krebs von den Lungen-6 (KL-6) in patients with early-stage silicosis and explore its potential as a diagnostic biomarker.</p><p><strong>Methods: </strong>Blood samples were collected from 40 stage I silicosis patients, 57 dust-exposed workers (DEWs), and 70 healthy controls (HCs). The concentrations of KL-6, C-reactive protein (CRP), and angiotensin-converting enzyme (ACE) were measured using the automatic biochemical analyzer. Receiver operating characteristic (ROC) curve analysis was utilized to evaluate the diagnostic efficacy of KL-6, in combination with other biomarkers for the early stage of silicosis. The association between lung function and KL-6 levels in silicosis patients was evaluated using partial correlation analysis.</p><p><strong>Results: </strong>Serum levels of KL-6, CRP, and ACE were remarkably elevated in stage I silicosis patients compared to HCs and DEWs. KL-6 demonstrated an adjusted area under the curve (AUC) of 0.770 for distinguishing stage I silicosis patients from HCs, with a sensitivity of 80.0% and a specificity of 70.0%. When comparing silicosis patients to DEWs, KL-6 alone achieved an adjusted AUC of 0.735, with sensitivity and specificity of 45.0% and 89.5%, correspondingly. The integration of KL-6, CRP, and ACE demonstrated the highest diagnostic efficacy among all tested combinations. Furthermore, serum KL-6 levels were negatively correlated with vital capacity (VC) in silicosis patients.</p><p><strong>Conclusions: </strong>Serum KL-6 may serve as a potential biomarker for early silicosis diagnosis. Its diagnostic performance is significantly improved when combined with CRP ad ACE, offering a potential multi-biomarker approach for enhanced detection in the early stages of the disease. Further validation in larger and more diverse populations is needed to confirm its clinical utility.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"366"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12315361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of adult empyema thoracis cases managed in a tertiary hospital in Uganda: a retrospective cohort study.","authors":"Michael Mwesige, Paul Otim, Richard N Iranya, John Paul Magala, Timothy K Makumbi","doi":"10.1186/s12890-025-03861-0","DOIUrl":"10.1186/s12890-025-03861-0","url":null,"abstract":"<p><strong>Background: </strong>Empyema thoracis is a debilitating illness observed in all age groups. Recent data indicate increasing incidence rates and worsening outcomes. However, published data on the outcomes of empyema thoracis cases in our setting are scarce.</p><p><strong>Objective: </strong>This study evaluated outcomes and associated factors for adult empyema thoracis patients managed at a single tertiary center in Uganda.</p><p><strong>Methods: </strong>We reviewed the file records of patients 18 years or older who were managed for empyema thoracis at Mulago National Referral Hospital from January 2017 to December 2021. Sociodemographic data, comorbidities, clinical parameters at admission, and management strategies were reviewed. The outcomes of interest were in-hospital mortality and the need for re-intervention. A multivariate logistic regression model was used to identify independent factors associated with the need for re-intervention and in-hospital mortality.</p><p><strong>Results: </strong>A total of 200 case files were analyzed, and 123 (61.5%) of the cases were males. The median age of the cohort was 33 years (IQR = 21). The in-hospital mortality rate was 10.5% (21 patients), and 23.5% (47 patients) required one or more re-interventions. Advancing age (adjusted OR = 1.04 (1.01-1.08)) and non para-pneumonic underlying etiology (adjusted OR = 11.45 (2.74-47.89)) were independently associated with increased in-hospital mortality, whereas delayed empyema drainage (adjusted OR = 2.97 (1.33-6.67)) and underlying non para-pneumonic etiology (adjusted OR = 3.83 (1.45-10.10.10)) significantly increased the odds of the need for re-intervention in management.</p><p><strong>Conclusion: </strong>The in-hospital mortality and re-intervention rates for empyema thoracis were high in our study. Particularly at-risk groups for these poor outcomes are those with advanced age, non para-pneumonic empyema thoraces, and delayed initial intervention.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"365"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12315433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latent profile analysis for medication adherence in patients with chronic obstructive pulmonary disease.","authors":"Xiao-Qin Wang, Yu-Lin Lu, Juan Liu, Ping Zhang, Shu-Yu Shi, Yuan-Yuan Yi, Ping Wu, Xue-Mei Li, Kai Sun, Qing-Jie Chen","doi":"10.1186/s12890-025-03859-8","DOIUrl":"10.1186/s12890-025-03859-8","url":null,"abstract":"","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"363"},"PeriodicalIF":2.8,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12312328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of altitude and eosinophil with the one-year mortality of acute exacerbation of chronic obstructive pulmonary disease: a cohort study.","authors":"Junqing Li, Zhangchun He, Chengyue Zhu, Rongrong Li, Zixuan Zheng, Hanwei Zhao, Yue Dong, Zhijun Jie, Heyuan Ding, Jindong Shi","doi":"10.1186/s12890-025-03832-5","DOIUrl":"10.1186/s12890-025-03832-5","url":null,"abstract":"<p><strong>Background: </strong>Altitude and eosinophil (EOS) are closely related to chronic obstructive pulmonary disease (COPD). There are limited studies on the association of altitude and EOS with mortality of COPD patients. Our aim was to explore the association of altitude and EOS with one-year all-cause mortality of patients hospitalized for acute exacerbation of COPD (AECOPD).</p><p><strong>Methods: </strong>A total of 351 inpatients with AECOPD in two hospitals from 2021 to 2022 were enrolled and divided into two groups based on the altitude and followed up for one year. Logistic and Cox regression analyses were used to determine the relationship of altitude and eosinophil with one-year all-cause mortality. Restricted cubic spline (RCS) was used to investigate the relationship between variables and outcome. In addition, a post hoc analysis was conducted to explore the relationship between EOS and one-year mortality of AECOPD patients at high altitude.</p><p><strong>Results: </strong>Patients at high altitude had a higher one-year all-cause mortality compared with patients at low altitude (P = 0.001). Multivariate COX regression showed that altitude (HR 3.03, 95% CI 1.22-7.54, P = 0.017), age (HR 2.77, 95% CI 1.31-5.88, P = 0.008) and CRP (HR 2.62, 95% CI 1.29-5.29, P = 0.007) increased the mortality risk in AECOPD patients. BMI (HR 0.34, 95% CI 0.15-0.78, P = 0.011) and EOS (HR 0.16, 95% CI 0.04-0.68, P = 0.013) decreased the mortality risk in AECOPD patients. Age, BMI, EOS and CRP were linearly correlated with one-year mortality of AECOPD. A post hoc analysis revealed that EOS (HR 0.17, 95% CI 0.04-0.70, P = 0.014) decreased the mortality risk in AECOPD patients at high altitude.</p><p><strong>Conclusion: </strong>Patients with COPD at high altitude had a higher one-year mortality. Altitude and EOS are associated with one-year mortality in COPD patients, which underscores the potential therapeutic benefits of EOS in mitigating the mortality risk of AECOPD patients at high altitude.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"362"},"PeriodicalIF":2.8,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}